sydney meeting, page-8

Port,

Biota now has RSV, HCV and Gyrase. The company now has yet to decide which program(s) to advance first. If Gyrase is not the important one to advance, why did PC decide to made acquisition? It is just illogical. I just sense the smell of the former Babcock and Brown's management team out of this Biota management team. IMO, the last two acquisitions have turned out to be just unnecessary burdens on Biota financials, based what PC said in the last Openbriefing:

"CEO Peter Cook
...We focused our early stage research work on our gyrase program and turned off our other competing antibacterial programs, driven by the progress with gyrase. Our other antibacterial programs have been suspended unless they have attracted external funding.
Under our current plan, our clinical stage programs will focus on laninamivir. Because it’s fully funded, we’ll give maximum attention to that program. In the near term – six to nine months – we’ll be looking to advance one or more of the earlier stage, pre-clinical programs like RSV, or hepatitis C or gyrase programs. We have yet to decide which of these programs we’ll advance into the clinic. We’re looking to maintain cash burn at around $20 million a year; but at this stage we haven’t identified the specific programs or the extent of any clinical expenditure."

Just my opinions.